Gp96-Ig-secreting Allogeneic Tumor-Cell Vaccine HS110

A proprietary, allogeneic tumor cell vaccine expressing a recombinant secretory form of the heat shock protein gp96 fusion (gp96-Ig) with potential antineoplastic activity. Upon administration of gp96-Ig-secreting allogeneic tumor cell vaccine HS110, the irradiated live tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs) into the blood stream, thereby activating antigen presenting cells, natural killer cells and priming potent cytotoxic T lymphocytes (CTLs) to respond against TAAs on the endogenous tumor cells. Furthermore, this vaccine may induce long-lived memory T cells that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL retention sequence of gp96, normally an endoplasmatic reticulum-resident chaperone peptide, with the Fc portion of mouse and human IgG1. (NCI Thesaurus)

YOU MAY ALSO LIKE

gp96 HSP-peptide complex

A vaccine made from a patient’s tumor cells that may help the body’s immune system kill cancer cells. This vaccine is used…

Gp96 heat shock protein-peptide complex vaccine

A vaccine made from a patient’s tumor cells that may help the body’s immune system kill cancer cells. This vaccine is used…

gp209-2M Antigen

A modified peptide antigen derived from gp209, with potential immunomodulatory and antineoplastic activities. gp209-2M antigen (IMDQVPFSV) has a methionine substitution of threonine…

gp209-2M

A peptide (short piece of protein) made from the tumor-specific antigen gp100, and used to make vaccines being studied in the treatment…

GP2 Peptide/GM-CSF Vaccine

A vaccine containing a HER2/Neu-derived epitope (amino acids 654-662) (GP2), and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunoadjuvant…

gp100:614-622 Peptide

A synthetic peptide consisting of amino acid residues 614 through 622 of the melanoma-melanocyte antigen glycoprotein 100 (gp100). Vaccination with gp100:614-622 peptide…